Assessment of release kinetics of Docetaxel loaded PLGA nanoparticles

Mody, Nishi; Sharma, Rajeev; Vyas, Sameer

doi:10.31024/ajpp.2019.5.5.24

Cited by 3 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preformulation studies are defined as the preliminary process of determining the physicochemical properties of the drug and the excipients, which are crucial for the preparation of the effective, safe and highly stable dosage form [21]. These studies are carried out to determine the optimum conditions for the preparation of dosage forms with desired characteristics.…”

Section: Preformulation Studiesmentioning

confidence: 99%

“…The volumetric flask containing the immiscible phases with the Insulin was placed on an orbital shaker for 24 h at ambient room temperature. After the completion of 24 h both the phases i.e., organic and aqueous phases were separated using the separating funnel [21]. The concentration of the Insulin was determined in the aqueous phase using the UV Visible Spectrophotometer (Orion Aquamate 8000, Thermo Fisher Scientific, USA) at λmax 276 nm.…”

Section: Partition Coefficientmentioning

confidence: 99%

See 1 more Smart Citation

Formulation and in Vitro Characterisation of Glucose-Responsive Nanocapsules for the Delivery of M-Insulin

Vishwakarma

Vyas

2023

Int J App Pharm

Self Cite

View full text Add to dashboard Cite

Objective: The present study aimed to develop and characterize Chitosan coated Alginate Nanocapsules loaded with M-Insulin Concanavalin A Complex for glucose-responsive delivery. Methods: Preformulation studies were performed on the Insulin human recombinant and the Nanocapsules were prepared by the ionic gelation method and coated with chitosan using electrostatic attraction. The formulation variables were optimized using Box-Behnken design (BBD) with the help of Design-Expert® Software. Three independent variables taken were the concentration of chitosan (A1), the concentration of sodium alginate (A2), and the stirring rate (A3). The response variables selected were the average particle size (nm) (B1), polydispersity index (B2), and cumulative release (%) (B3). Results: The results from the Preformulation studies indicated that the received sample of the Insulin human recombinant was pure. The optimized nanocapsules possessed an average particle size of 382.4 nm, PDI 0.211 and zeta potential of 30.25 mV. The entrapment efficiency was found to be 79.2 %. The nanocapsules were further characterized for their surface morphology using TEM and were found to be of regular shape. The in vitro drug release study indicated that the nanocapsules were able to release 58 % of M-insulin in hyperglycaemic conditions for 12 h. Conclusion: The outcomes of the study demonstrated that the developed nanocapsules can be effectively used for glucose-responsive delivery of M-insulin.

show abstract

Section: Preformulation Studiesmentioning

confidence: 99%

Section: Partition Coefficientmentioning

confidence: 99%

Formulation and in Vitro Characterisation of Glucose-Responsive Nanocapsules for the Delivery of M-Insulin

Vishwakarma

Vyas

2023

Int J App Pharm

Self Cite

View full text Add to dashboard Cite

show abstract

Design, synthesis, and antitumor activity of PLGA nanoparticles incorporating a discovered benzimidazole derivative as EZH2 inhibitor

Elkot

Ragab

Saleh

et al. 2021

Chemico-Biological Interactions

View full text Add to dashboard Cite

Dexamethasone encapsulated PLGA nanoparticles for the treatment of neuroinflammation

Stephen

Chokriwal

Sharma

et al. 2022

Bioinspired, Biomimetic and Nanobiomaterials

View full text Add to dashboard Cite

Neuroinflammation is a condition that contribute significantly to the pathogenesis and progression of several neurodegenerative disorders. Targeting neuroinflammation is a novel therapeutic approach for the treatment of these disorders. Dexamethasone is a steroidal based anti-inflammatory drug with the potential to treat neuroinflammation. However, in order to maintain the efficacy of the drug, dexamethasone needs to be coupled with an effective drug delivery vehicle to be able to be transported across Central Nervous System. PLGA nanoparticles has been used as drug delivery vehicles for transport of drugs into the central nervous system. The article describes the preparation and encapsulation of dexamethasone loaded PLGA nanoparticles by solvent evaporation method. Statistical Experimental Design approach was performed, wherein Response Surface Methodology was carried out to optimize the parameters associated with synthesis process. Further, kinetic modeling and drug release profile were also determined. The drug encapsulated nanoparticles were validated for its effectiveness in vitro. Toxicity studies revealed the nanodrug to be non-cytotoxic and Griess assay highlighted its ability to lower neuroinflammation. Further, genetic studies revealed the anti-inflammatory properties of the nanodrug was successfully in modulating neuroinflammation.

show abstract

Assessment of release kinetics of Docetaxel loaded PLGA nanoparticles

Cited by 3 publications

References 14 publications

Formulation and in Vitro Characterisation of Glucose-Responsive Nanocapsules for the Delivery of M-Insulin

Formulation and in Vitro Characterisation of Glucose-Responsive Nanocapsules for the Delivery of M-Insulin

Design, synthesis, and antitumor activity of PLGA nanoparticles incorporating a discovered benzimidazole derivative as EZH2 inhibitor

Dexamethasone encapsulated PLGA nanoparticles for the treatment of neuroinflammation

Contact Info

Product

Resources

About